Navigation Links
NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
Date:11/30/2007

HELSINGBORG, Sweden, November 30 /PRNewswire/ -- NOLabs AB, the Swedish medtech company developing innovative nitric oxide-containing medical devices based on the NitroSense(R) Technology, today reported that it has achieved another important milestone in the development of a new line of products for wounds infected by MRSA-bacteria. MRSA stands for Methicillin Resistant Staphylococcus aureus, a bacterium that is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.

In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs' technology has a promising ability to kill a wide range of pathogens, including MRSA.

According to the US Centers for Disease Control and Prevention 126,000 hospitalisations are related to MRSA and 19,000 deaths are associated with serious MRSA infections every year in U.S. hospitals. Patients at risk for infection with MRSA include those with severe disease, recent surgery or indwelling medical devices, such as urinary catheters.

Goran Beijer, CEO of NOLabs says: "The recent results show that we are on the right track towards products with an enormous potential globally. The anti-microbial effect of NO will be key in several products that will prevent and/or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008."

NOLabs' NitroSense(R) Technology assures controlled, local delivery of pure nitric oxide in a well-defined concentration range during a well-defined time period. The main areas are prevention of catheter related urinary tract infections, relief of neuropathic pain and wound care products with an anti-bacterial effect.

For more information please visit our home page: http://www.nolabs.com

NOLabs is a Swedish medtech company developing and marketing nitric oxide-containing medical devices for various medical applications. Nitric oxide is a natural substance, produced by the human body. Its physiological effects include the control of local blood supply and the protection against microbes. In particular, NOLabs focuses on prevention of infection and pain relief for patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of catheter-associated urinary tract infections. NOLabs has developed the innovative, cost efficient and highly effective NitroSense(R) Technology with a significant potential to address serious health issues that impact the lives of over 100 million people.

Goran Beijer,

E-mail goran.beijer@nolabs.com,

Phone: +46-42-33-65-22;

Susanne Goransson,

E-mail: susanne.goransson@nolabs.com,

Phone: +46-42-33-65-30.


'/>"/>
SOURCE NOLabs AB
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
3. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Soap and Water May not be Enough to Fight MRSA Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone ... continued commitment to the advancement of the clinical trials segment. Hosted in Miami, ... clinical trial planning and management. , As executive talent specialists in the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced ... Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the ... the Department of Defense has announced the award of a new Advanced Regenerative ...
(Date:1/18/2017)... PA (PRWEB) , ... January 18, 2017 , ... ... operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency ... engaging panel discussions to examine vital clinical research issues such as trial performance ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much ... doors or starting the engine. Continental will demonstrate the ... Las Vegas . Through the combination of ... and Entry) and biometric elements, the international technology company ... vehicle personalization and authentication. "The integration of ...
Breaking Biology News(10 mins):